RxDoctor Payments Data

Michael Madden, MD

Family Medicine · Mobile, ALNPI 1861444689

Payments from drug & device makers

$374in general payments, 2019–2025

Across 21 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$68
  • Otsuka America Pharmaceutical, Inc.$64
  • Lilly USA, LLC$59
  • Shield Therapeutics Inc$41
  • AstraZeneca$40
  • Johnson & Johnson$29
  • plus $73 from 5 others

What the payments were for

  • Food & beverage$374100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$374 in reported general payments places this provider in the 40th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$67,410
Medicare patients
88
Services billed
1,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$83,124
JanuviaSitagliptin Phosphate122$82,026
EliquisApixaban97$76,411
Invega SustennaPaliperidone Palmitate18$66,023
FarxigaDapagliflozin Propanediol45$46,482
XareltoRivaroxaban38$35,298
LinzessLinaclotide46$34,074
MounjaroTirzepatide28$32,290
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl154$31,122
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$28,571
JardianceEmpagliflozin37$28,039
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,039$24,874
RexultiBrexpiprazole15$24,556
Breo ElliptaFluticasone/Vilanterol23$13,472
UbrelvyUbrogepant12$11,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Xarelto$29$101,32156 claims
PfizerEliquis$68$76,41197 claims
AstraZenecaFarxiga$40$46,48245 claims
AbbVieLinzess, Ubrelvy$11$45,67758 claims
GSKTrelegy Ellipta, Breo Ellipta$19$42,04359 claims
Lilly USA, LLCMounjaro$59$32,29028 claims
Otsuka America Pharmaceutical, Inc.Rexulti$64$24,55615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →